SYDNEY, AUSTRALIA, November 02, 2021 (GLOBE NEWSWIRE) – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, has the Pleased to announce the granting of a new patent (number ZL 201610221687) entitled “Use of Recombinant LAG-3 or its Derivatives to Trigger a Monocytic Immune Response” by the Chinese Patent Office. The patent is part of a large and growing portfolio of patent families for the Company’s flagship product, candidate eftilagimod alpha (“efti” or “IMP321”) in major global markets, including China.
This new Chinese patent follows the granting of the corresponding European, Japanese and American patents announced previously. The claims of the new patent relate to methods of using (a) the efi of Immutep which is a LAG-3 (LAG-3Ig) fusion protein and (b) a chemotherapy agent in combination for the manufacture of a preparation for the treatment of cancer. The patent offers protection in mainland China and the expiration date is October 3, 2028.
The new patent is owned by Immutep SAS and under exclusive license to Immutep’s partner in China, EOC Pharma (“EOC”).
Immutep CEO, Marc Voigt, Noted: “We are making good progress in building our global patent heritage around our LAG-3 development pipeline, including lead candidate efti which has provided promising clinical data in a variety of settings. We will continue to make these important investments and are particularly pleased to work so closely with our Chinese partner, EOC Pharma, as they expand their clinical development of efti for the Chinese market. “
EOC Pharma CEO Xiaoming Zou said: “We are investing in the development of efi for the local market in China and are very satisfied with the measures taken by our partner, Immutep, to build a large portfolio of patent families around this unique candidate. These are important and ongoing steps in the complex process of bringing innovative medicines to market for patients. “
On efti in china
Efti is exclusively licensed from Immutep to EOC Pharma for the Greater China Territory (namely Mainland China, Hong Kong SAR, Macao SAR and Taiwan). Under its agreement with Immutep, EOC will make further milestone payments to the Company if it reaches specific development milestones, as well as royalties based on sales. Immutep retains the efi rights outside of Greater China Territory.
About EOC Pharma
EOC Pharma is an integrated biopharmaceutical company focused on the discovery, research, development and commercialization of innovative oncology products. With an insight-driven strategy and an integrated business platform, EOC Pharma strives to create a product portfolio with strategic synergies from independent R&D and licensing and to enrich the product portfolio with drugs Class-leading, best-in-class oncologists benefiting millions of patients. who currently have limited access to high quality cancer treatments in China.
Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutics related to LAG-3 for the treatment of cancer and autoimmune diseases. Immutep is committed to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value.
Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a currently first class antigen presenting cell (APC) activator. explored in cancer and infectious diseases. Immutep is also developing a LAG-3 agonist (IMP761) for autoimmune diseases. Other LAG-3 products, including antibodies for modulating the immune response, are under development by Immutep’s major pharmaceutical partners.
Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.
Further information can be found on the company’s website www.immutep.com or by contacting:
Australian Investors / Media:
Catherine Strong, Citadelle-MAGNUS
+61 (0) 406 759 268; [email protected]
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]